Therapeutic evaluation of GM2 gangliosidoses by ELISA using anti-GM2 ganglioside antibodies.

Abstract

BACKGROUND GM2 gangliosidoses, including Tay-Sachs disease, Sandhoff disease and the AB variant, comprise deficiencies of beta-hexosaminidase isozymes and GM2 ganglioside activator protein associated with accumulation of GM2 ganglioside (GM2) in lysosomes and neurosomatic clinical manifestations. A simple assay system for intracellular quantification of GM2… (More)

Topics

Cite this paper

@article{Tsuji2007TherapeuticEO, title={Therapeutic evaluation of GM2 gangliosidoses by ELISA using anti-GM2 ganglioside antibodies.}, author={Daisuke Tsuji and Yukari Higashine and Kazuhiko Matsuoka and Hitoshi Sakuraba and Kohji Itoh}, journal={Clinica chimica acta; international journal of clinical chemistry}, year={2007}, volume={378 1-2}, pages={38-41} }